A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

Exclusion Criteria

• •Patients out of weight range
• •Ongoing or previous treatment with immunomodulatory drugs
• •* A limited number of Still's Disease patients that have previously received MAS825 through a managed access program are permitted on the study
• •Glucocorticoid dose exceeding a set limit
• •Any conditions or significant medical problems which places the patient at unacceptable risk for MAS825 therapy
• •* Still's disease patients with evidence of macrophage activation syndrome are permitted in the study
• •* Still's Disease patients with evidence of interstitial lung disease including those requiring supplemental oxygen therapy are permitted in the study
• •History of ongoing, chronic or possibly recurrent infection (e.g. HIV, TB, HCV, HBV) and/or symptoms and signs of clinically significant active bacterial, fungal or viral infections
• •Live vaccinations within a set time prior to MAS825 treatment. Live vaccines are prohibited up to several months following the last dose
• •History of malignancy of any organ system, including post-transplant lymphoproliferative disorder, treated or untreated, within a number of years, regardless of whether there is evidence of local recurrence and metastases
• •History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or to any of the excipients
• •Pregnant or breastfeeding women
• •Women of child-bearing potential who do not agree to comply with required contraceptive use